KT Medical Service PCL vs Tenet Healthcare: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

KT Medical Service PCL (KTMS.BK)

Q3 202619 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

September 202619 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

Latest19 Aug – 4 Oct 2026

▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.
It shows the main business is growing and expanding, directly driving future revenue and profit.
High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.
It explains the underlying demand that supports KTMS's expansion and revenue targets.
Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.
It is a real counterweight that could slow near-term revenue recognition and pressure the stock.
Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.
It gives a forward-looking positive catalyst that could drive the stock higher.

Tenet Healthcare Corporation (THC)

Q3 202621 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

August 202621 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

Latest21 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.